Study | Year | Country | Study design | Gender (M/F) | Sample size VATS/MST | Staging | Propensity score matching | Quality assessment |
---|---|---|---|---|---|---|---|---|
Giudicelli | 1994 | France | Prospective | 50/17 | 44/23 | Pathologic Stage I to stage IV | Unmatched | NOS: 6 |
Kirby | 1995 | USA | RCT | 26/35 | 30/31 | Clinical stage I | Unmatched | Jadad: 1 |
Nomori | 2001 | Japan | Prospective | 44/22 | 33/33 | Clinical stage I | Unmatched | NOS: 8 |
Wang | 2010 | China | Retrospective | 175/141 | 121/195 | Pathologic Stage I to stage IV | Unmatched | NOS: 6 |
Ilonen | 2013 | Finland | Retrospective | 125/107 | 116/116 | Clinical stage I | Matched | NOS: 7 |
Erus | 2014 | Turkey | Prospective | 35/20 | 25/30 | Clinical stage I | Unmatched | NOS: 8 |
Kuritzky | 2015 | USA | Retrospective | 45/75 | 60/60 | Clinical stage I | Matched | NOS: 8 |
Usuda | 2017 | Japan | Retrospective | 46/41 | 25/62 | Clinical Stage I to stage III | Unmatched | NOS: 6 |
Zhao | 2017 | China | Retrospective | 250/232 | 241/241 | Clinical stage I | Matched | NOS: 8 |
Menna | 2018 | Italy | Retrospective | 18/10 | 16/12 | Clinical Stage I | Unmatched | NOS: 7 |